Blog and Whitepapers

Recon takes an analytical look behind select developments in healthcare

Denali Therapeutics’ recent accelerated approval of AVLAYAH, an enzyme replacement therapy for Hunter syndrome (MPS II), is a milestone accomplishment in blood brain barrier (BBB)-crossing technology.…
We use cookies
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.